Neupeg 6 mg Inj

Pegfilgrastim, the active ingredient in Neupeg, belongs to a class of medications known as granulocyte colony-stimulating factors (G-CSFs), which work by stimulating the bone marrow to produce more neutrophils, a type of white blood cell essential for fighting infection. Chemotherapy can significantly reduce neutrophil counts, a condition known as neutropenia, which increases the risk of serious infections during cancer treatment. By boosting neutrophil production, Neupeg helps reduce the duration and severity of chemotherapy-induced neutropenia, supporting the patient's ability to continue their cancer treatment on schedule. Being a "pegylated" formulation, Pegfilgrastim has a longer duration of action compared to standard filgrastim, allowing for a single injection per chemotherapy cycle rather than daily injections, offering greater convenience for patients. The 6mg pre-filled syringe is typically administered once per chemotherapy cycle, usually about 24 hours after chemotherapy is completed, as directed by an oncology healthcare provider. Regular monitoring, including blood counts, helps track the patient's response and ensure the treatment is working as intended to support immune function during cancer treatment. Many patients experience meaningful reduction in infection risk and are better able to maintain their planned chemotherapy schedule with the support of Neupeg. As with all supportive cancer care medications, Neupeg should be administered under the guidance of an experienced oncology healthcare team as part of a comprehensive treatment plan.